Adverum Biotechnologies logo
Adverum Biotechnologies ADVM

Quarterly report 2025-Q3
added 11-12-2025

report update icon

Adverum Biotechnologies Cash Flow 2011-2026 | ADVM

Annual Cash Flow Adverum Biotechnologies

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-92.5 M -90.9 M -108 M -108 M -79.3 M -49.2 M -54 M -45.4 M - - - - - -

Depreciation & Amortization

3.65 M 5.64 M 6.53 M 4.64 M 4.16 M 1.57 M 1.75 M 2.1 M 1.6 M 812 K 162 K 26 K 1 K -

Accounts Payables

1.61 M 1.92 M 2.24 M 1.39 M 2.81 M 4.1 M 1.71 M 1.73 M 1.47 M 605 K 951 K - - -

Accounts Receivables

- - - - - - - - 886 K 449 K - - - -

All numbers in USD currency

Quarterly Cash Flow Adverum Biotechnologies

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -42.8 M - - -23.2 M - - -22.4 M - -89.6 M -57.8 M -28.9 M - -82 M -56.2 M -22.3 M - -57.1 M -30.5 M -13.6 M - -34.3 M -24.8 M -13.2 M - -41.2 M -24.3 M -13 M - -33.2 M -23.2 M - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

- - 683 K - - 997 K - - 1.59 M - 4.82 M 3.03 M 1.42 M - 3.32 M 2.36 M 1.17 M - 1.2 M 1.3 M 599 K - 400 K 400 K 426 K - 400 K 500 K 459 K - 500 K 600 K 516 K - 400 K 300 K 320 K - 241 K 147 K 118 K - 49 K 25 K 9 K - 7 K 7 K - - - - - - - - -

Accounts Payables

12.5 M 4.75 M 1.82 M 2.11 M 1.97 M 1.9 M 2.17 M 1.42 M 2.86 M 2.24 M 846 K 4.7 M 3.24 M 1.39 M 2.52 M 2.26 M 2.06 M 2.81 M 2.81 M 2.81 M 2.81 M 4.1 M 4.1 M 4.1 M 4.1 M 1.71 M 1.71 M 1.71 M 1.71 M 1.73 M 1.73 M 1.73 M 1.73 M 1.47 M 1.47 M 1.47 M 1.47 M 605 K 605 K 605 K 605 K 951 K 951 K 951 K 951 K 769 K 769 K 769 K - - - - - - - - -

Accounts Receivables

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 886 K 886 K 886 K 886 K 449 K 449 K 449 K 449 K - 8 K 8 K - 8 K 8 K 8 K - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Adverum Biotechnologies, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
AbbVie AbbVie
ABBV
$ 232.08 3.29 % $ 411 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.61 0.56 % $ 1.08 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.12 -1.54 % $ 109 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.66 -0.85 % $ 773 M canadaCanada
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 24.56 -0.32 % $ 4.07 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 4.56 -3.59 % $ 90.4 M usaUSA
AC Immune SA AC Immune SA
ACIU
$ 2.93 -1.01 % $ 229 M schweizSchweiz
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 2.87 -8.31 % $ 352 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Adagene Adagene
ADAG
$ 2.96 -4.67 % $ 167 M chinaChina
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.1 -0.73 % $ 105 M schweizSchweiz
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 2.53 - $ 16.4 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
$ 15.57 2.57 % $ 3.71 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 16.02 -2.67 % $ 2.43 B usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 0.46 -4.63 % $ 6.06 K usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Agenus Agenus
AGEN
$ 3.33 -0.89 % $ 1.19 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 30.23 0.83 % $ 1.75 B usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.91 -8.59 % $ 43.8 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.31 -0.76 % $ 337 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 0.24 -8.87 % $ 5.73 B britainBritain
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 5.46 -0.73 % $ 328 M usaUSA
Alector Alector
ALEC
$ 2.43 -5.08 % $ 250 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 7.03 -6.27 % $ 452 M usaUSA
Alkermes plc Alkermes plc
ALKS
$ 30.1 -2.05 % $ 4.96 B irlandaIrlanda
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 2.78 1.83 % $ 436 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 332.92 0.51 % $ 43.6 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Altimmune Altimmune
ALT
$ 4.31 -3.36 % $ 306 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 2.11 -10.21 % $ 110 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Amgen Amgen
AMGN
$ 388.16 2.33 % $ 209 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA